Q1 2026 Merck & Co Inc Earnings Call Transcript
Key Points
- Merck & Co Inc (MRK) reported a year-over-year revenue growth to $16.3 billion, driven by strong performance in oncology and animal health.
- The company achieved several important pipeline milestones, including FDA approval for IDVYNSO for HIV-1 treatment and priority review for I-DXd in lung cancer.
- Merck & Co Inc (MRK) is undergoing a portfolio transformation with over 20 new product launches, many with blockbuster potential.
- The company announced a multiyear partnership with Google Cloud to enhance AI capabilities, complementing collaborations with Tempus AI and Mayo Clinic.
- Merck & Co Inc (MRK) has a robust pipeline with expectations for significant Phase 3 data readouts over the next 18 months, indicating strong future growth potential.
- GARDASIL sales decreased by 22% due to lower demand in China and Japan, impacting overall vaccine sales.
- The company reported a loss of $1.28 per share, including a significant negative impact from a $9 billion onetime charge related to the acquisition of Cidara Therapeutics.
- Sales of OHTUVAYRE were adversely impacted by CMS reimbursement changes and Medicare deductible resets.
- Merck & Co Inc (MRK) faces challenges in the competitive immunology market, which is largely portfolio-driven by peers with larger offerings.
- The proposed acquisition of Terns Pharmaceuticals is expected to result in a onetime charge, increasing R&D expenses and negatively impacting EPS by approximately $0.12 this year.
Thank you for standing by. Welcome to the Merck & Co., Inc. Rahway, New Jersey, USA, first-quarter sales, and earnings conference call. (Operator Instructions)
This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.
Thank you, Julie, and good morning, everyone. Welcome to the first-quarter 2026 conference call for Merck & Co, inc. Rahway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Research Labs.
Before we get started, I'd like to point out that we have items in our GAAP results such as acquisition-related charges, restructuring costs and certain other items that we have excluded from our non-GAAP results. There is a reconciliation in our press release.
I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
